64 search results for: mechanism of disease

2025 ADVENT Forum | Remodeling in the Airway: A Damaged State <b>of</b> Affairs
Type 2 Inflammation
2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs
expert video

Explore the intricate world of airway remodeling with this comprehensive recording of the live session held at the 2025 ADVENT Forum: "Remodeling in the Airway: A Damaged State of Affairs." Moderated by Dr. Stella Lee, this session brings together a powerhouse multidisciplinary panel to dissect the multifaceted nature of airway damage.

View more
The Role <b>of</b> Type 2 Inflammation in Multiple <b>Disease</b> Trajectories
Dermatology
The Role of Type 2 Inflammation in Multiple Disease Trajectories
Infographic

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

View more
CEORL-HNS 2026 | Emerging Evidence <b>of</b> Biologics for the Treatment Landscape <b>of</b> CRSwNP
Rhinology
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
expert video

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

View more
COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
COPD and Asthma: What's the Difference and Is There a Link?
interactivity

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

View more
EAPS
On Demand
Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

The Benefits <b>of</b> Early Intervention in Reducing the Burden <b>of</b> <b>Disease</b> in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

thumbnail
Congress
17
May
2026
Congress
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Key Pathophysiological <b>Mechanism</b>s <b>of</b> Chronic Spontaneous Urticaria Are Driven by Type 2 Inflammation
Dermatology
Key Pathophysiological Mechanisms of Chronic Spontaneous Urticaria Are Driven by Type 2 Inflammation
expert video

Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.

View more
Coexisting Type 2 Inflammatory <b>Disease</b>s Can Add to the Patient Overall <b>Disease</b> Burden
Type 2 Inflammation
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares highlights how patients with type 2 inflammatory diseases often experience multimorbidities, with overlapping symptoms that amplify their overall disease burden and impact quality of life.

View more
Which Biomarkers <b>of</b> AD Might Be Robust Enough to Be Evaluated as a Measure <b>of</b> <b>Disease</b> Modification?
Dermatology
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.

View more
Shared and Distinct: The Role <b>of</b> Type 2 Inflammation in Skin <b>Disease</b>s
Dermatology
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
expert video

Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively. 

View more